These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 21244344)

  • 1. Update on the endocannabinoid system as an anticancer target.
    Malfitano AM; Ciaglia E; Gangemi G; Gazzerro P; Laezza C; Bifulco M
    Expert Opin Ther Targets; 2011 Mar; 15(3):297-308. PubMed ID: 21244344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the endocannabinoid system as a potential anticancer approach.
    Schwarz R; Ramer R; Hinz B
    Drug Metab Rev; 2018 Feb; 50(1):26-53. PubMed ID: 29390896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
    Petrosino S; Di Marzo V
    Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1.
    Palumbo-Zerr K; Horn A; Distler A; Zerr P; Dees C; Beyer C; Selvi E; Cravatt BF; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 Dec; 71(12):2051-4. PubMed ID: 22915616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system.
    Lenman A; Fowler CJ
    Br J Pharmacol; 2007 Aug; 151(8):1343-51. PubMed ID: 17592505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut feelings about the endocannabinoid system.
    Di Marzo V; Piscitelli F
    Neurogastroenterol Motil; 2011 May; 23(5):391-8. PubMed ID: 21481098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure.
    Weis F; Beiras-Fernandez A; Sodian R; Kaczmarek I; Reichart B; Beiras A; Schelling G; Kreth S
    J Mol Cell Cardiol; 2010 Jun; 48(6):1187-93. PubMed ID: 19931541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
    Svízenská I; Dubový P; Sulcová A
    Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid signaling and liver therapeutics.
    Mallat A; Teixeira-Clerc F; Lotersztajn S
    J Hepatol; 2013 Oct; 59(4):891-6. PubMed ID: 23567085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.
    Hungund BL; Basavarajappa BS
    Ann N Y Acad Sci; 2004 Oct; 1025():515-27. PubMed ID: 15542757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latest advances in cannabinoid receptor agonists.
    Thakur GA; Tichkule R; Bajaj S; Makriyannis A
    Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects.
    Zogopoulos P; Vasileiou I; Patsouris E; Theocharis S
    J Appl Toxicol; 2013 Apr; 33(4):246-64. PubMed ID: 23296873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
    Janero DR; Makriyannis A
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of endocannabinoid 1 and 2 (CB1; CB2) receptor agonists on luteal weight, circulating progesterone, luteal mRNA for luteinizing hormone (LH) receptors, and luteal unoccupied and occupied receptors for LH in vivo in ewes.
    Tsutahara NM; Weems YS; Arreguin-Arevalo JA; Nett TM; LaPorte ME; Uchida J; Pang J; McBride T; Randel RD; Weems CW
    Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):17-24. PubMed ID: 21109016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoids and neurodegenerative diseases.
    Micale V; Mazzola C; Drago F
    Pharmacol Res; 2007 Nov; 56(5):382-92. PubMed ID: 17950616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective cannabinoid receptor 2 modulators: a patent review 2009--present.
    Riether D
    Expert Opin Ther Pat; 2012 May; 22(5):495-510. PubMed ID: 22537079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of cannabinoid receptor ligands: current status.
    Singh J; Budhiraja S
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligands for cannabinoid receptors, promising anticancer agents.
    Nikan M; Nabavi SM; Manayi A
    Life Sci; 2016 Feb; 146():124-30. PubMed ID: 26764235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
    Loría F; Petrosino S; Mestre L; Spagnolo A; Correa F; Hernangómez M; Guaza C; Di Marzo V; Docagne F
    Eur J Neurosci; 2008 Aug; 28(4):633-41. PubMed ID: 18657182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The skeletal endocannabinoid system: clinical and experimental insights.
    Raphael B; Gabet Y
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):237-45. PubMed ID: 26457774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.